Anavex life sciences announces anavex®2-73 (blarcamesine) biomarker correlated with efficacy endpoints in placebo-controlled u.s. phase 2 clinical trial for the treatment of adult patients with rett syndrome

Anavex®2-73 treatment resulted in significant increase in the expression of the sigmar1 mrna biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints rsbq (p = 0.035) and cgi-i (p = 0.029)

AVXL Ratings Summary

AVXL Quant Ranking